000144020 001__ 144020
000144020 005__ 20240229121830.0
000144020 0247_ $$2doi$$a10.1161/JAHA.118.011882
000144020 0247_ $$2pmid$$apmid:31189389
000144020 0247_ $$2altmetric$$aaltmetric:62847746
000144020 037__ $$aDKFZ-2019-01571
000144020 041__ $$aeng
000144020 082__ $$a610
000144020 1001_ $$aJansen, Henning$$b0
000144020 245__ $$aRepeat Measurements of High Sensitivity Troponins for the Prediction of Recurrent Cardiovascular Events in Patients With Established Coronary Heart Disease: An Analysis From the KAROLA Study.
000144020 260__ $$aNew York, NY$$bAssociation$$c2019
000144020 3367_ $$2DRIVER$$aarticle
000144020 3367_ $$2DataCite$$aOutput Types/Journal article
000144020 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1564996926_11705
000144020 3367_ $$2BibTeX$$aARTICLE
000144020 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144020 3367_ $$00$$2EndNote$$aJournal Article
000144020 520__ $$aBackground High-sensitivity cardiac troponins T and I (hs- cTnT and hs- cTnI ) are established biomarkers for myocardial injury and used for diagnostic and prognostic purposes. However, whether repeat measurements improve prediction of recurrent cardiovascular disease ( CVD ) events in patients with stable coronary heart disease ( CHD ) after adjustment for several other novel biomarkers remains unclear. Methods and Results We measured both troponins in 873 coronary heart disease patients from the KAROLA (Langzeiterfolge der Kardiologischen Anschlussheilbehandlung) study about 9 weeks after their initial acute event (baseline) and after 12 months, followed them for 12 years, assessed a combined CVD end point, and adjusted for several risk factors. As we found evidence for effect modification, results were stratified according to presence of myocardial infarction at baseline. During follow-up, 186 fatal and non-fatal CVD events occurred. Both baseline and 12-months troponin concentrations were significantly associated with CVD events in patients without myocardial infarction at baseline; in tendency 12 months of troponin showed stronger hazard ratios (hs- cTnT : hazard ratios 1.91 (95% CI 1.17-3.11) versus baseline values 1.71 (95% CI 1.08-2.70) and for hs- cTnI : hazard ratio 1.55 (95% CI 1.05-2.30) versus baseline value 1.22 (95% CI 0.88-1.68) in the fully and simultaneously adjusted model. Conclusions Both troponins are consistently associated with recurrent cardiovascular events after adjustment for emerging risk factors during follow-up in our study especially evident in patients without myocardial infarction at baseline. Troponin values at 12 months of follow-up showed independent associations with future CVD events in addition to baseline assessments of troponins.
000144020 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000144020 588__ $$aDataset connected to CrossRef, PubMed,
000144020 7001_ $$aJaensch, Andrea$$b1
000144020 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b2$$udkfz
000144020 7001_ $$aDallmeier, Dhayana$$b3
000144020 7001_ $$aSchmucker, Roman$$b4
000144020 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$udkfz
000144020 7001_ $$aKoenig, Wolfgang$$b6
000144020 7001_ $$0P:(DE-HGF)0$$aRothenbacher, Dietrich$$b7$$eLast author
000144020 773__ $$0PERI:(DE-600)2653953-6$$a10.1161/JAHA.118.011882$$gVol. 8, no. 12$$n12$$pe011882$$tJournal of the American Heart Association$$v8$$x2047-9980$$y2019
000144020 909CO $$ooai:inrepo02.dkfz.de:144020$$pVDB
000144020 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144020 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144020 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000144020 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000144020 9141_ $$y2019
000144020 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ AM HEART ASSOC : 2017
000144020 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144020 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144020 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144020 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144020 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000144020 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000144020 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review
000144020 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ
000144020 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144020 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144020 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144020 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144020 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000144020 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000144020 980__ $$ajournal
000144020 980__ $$aVDB
000144020 980__ $$aI:(DE-He78)C070-20160331
000144020 980__ $$aI:(DE-He78)C120-20160331
000144020 980__ $$aUNRESTRICTED